TransCode Therapeutics (RNAZ) started dosing the first patient in the fourth cohort of its phase 1 cancer treatment trial.
Two more patients in the cohort are set to receive the TTX-MC138 "to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metastatic cancer," the company said Thursday in a statement.
"No significant safety or dose limiting toxicities have been reported," and additional patients are being evaluated for expanded enrollment, the company said.
Shares of the company rose 28% in after-hours trading.
Price: 0.6650, Change: +0.15, Percent Change: +27.88
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments